Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Travere Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare kidney and metabolic diseases. Its core products include FILSPARI (sparsentan) for IgA nephropathy and FSGS, and pegtibatinase for homocystinuria. The company leverages clinical expertise, innovative pipeline development, and strategic licensing to address significant unmet medical needs in niche markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.